Ovax

Ovax Inc. (now known as ARMR Sciences) is a clinical-stage biotechnology company focused on developing vaccines to combat the opioid crisis, specifically targeting fentanyl. The company's lead candidate, Fentanyl Armour, is an immunotherapeutic vaccine designed to generate antibodies that bind to fentanyl molecules in the bloodstream, preventing them from crossing the blood-brain barrier and neutralizing their lethal respiratory effects. By blocking both the euphoric high and the potential for overdose, Ovax aims to provide a long-term preventative solution for individuals with opioid use disorder and protective coverage for first responders. The company emerged from stealth in 2024 with significant seed funding and is advancing intellectual property licensed from the University of Houston through early-stage human clinical trials.